Join Growin Stock Community!

Entera bio ltd.ENTX.US Overview

US StockHealthcare
(No presentation for ENTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ENTX AI Insights

ENTX Overall Performance

ENTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ENTX Recent Performance

4.48%

Entera bio ltd.

1.63%

Avg of Sector

0.63%

S&P500

ENTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ENTX Key Information

ENTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ENTX Profile

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Price of ENTX

ENTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ENTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
514.04
PB Ratio
4.55
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
0.00%
Net Margin
-8694.35%
Revenue Growth (YoY)
25.25%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
514.04
PB Ratio
4.55
Price-to-FCF
-
Gross Margin
0.00%
Net Margin
-8694.35%
Revenue Growth (YoY)
25.25%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ENTX's latest earnings report released?

    The most recent financial report for Entera bio ltd. (ENTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ENTX's short-term business performance and financial health. For the latest updates on ENTX's earnings releases, visit this page regularly.

  • How is ENTX's revenue growth?

    In the latest financial report, Entera bio ltd. (ENTX) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ENTX have?

    As of the end of the reporting period, Entera bio ltd. (ENTX) had total debt of 211K, with a debt ratio of 0.01. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ENTX have?

    At the end of the period, Entera bio ltd. (ENTX) held Total Cash and Cash Equivalents of 16.6M, accounting for 0.95 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ENTX's EPS continuing to grow?

    According to the past four quarterly reports, Entera bio ltd. (ENTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ENTX?

    Entera bio ltd. (ENTX)'s Free Cash Flow (FCF) for the period is -2.55M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 18.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.